- Home
- Equipment
- asia middle east
- rare disease day 2017 with a commitment to provide new insights into rare diseases
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Rare Disease Day 2017 With A Commitment To Provide New Insights Into Rare Diseases Equipment Supplied In Asia Middle East
5 equipment items found
Distributed by:Salehiyah Establishment based inRiyadh, SAUDI ARABIA
Explore our diversified portfolio of pharmaceuticals, as we deliver the right medication to the right patient at the right time, covering some of the most critical needs of patients in the Kingdom. ...
Manufactured by:Suvoda based inConshohocken, PENNSYLVANIA (USA)
Our advanced patient randomization and trial supply management system. Your clinical trial command and control ...
Manufactured by:BRIM Biotechnology, Inc. based inTaipei City, TAIWAN
Neurotrophic Keratitis is a rare, degenerative disease characterised by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. Currently, there is only one drug, Oxervate (Cenegermin), approved by the US FDA and EMA in 2018. Eye health is crucial to quality of life and BRIM is advancing new therapeutics to support patients affected by Neurotrophic ...
Manufactured by:Kangstem Biotech Co., Ltd. based inGangnam-gu, SOUTH KOREA
Kangstem Biotech is developing stem cell therapeutic products for patients suffering from rare and incurable diseases using umbilical cord blood-derived stem ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...